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Abstract
Background: Mucosal specimens are essential to evaluate compartmentalized immune responses to HIV vaccine candidates
and other mucosally targeted investigational products. We studied the acceptability and feasibility of repeated mucosal
sampling in East African clinical trial participants at low risk of HIV and other sexually transmitted infections.
Methods and Findings: The Kenya AIDS Vaccine Initiative (KAVI) enrolled participants into three Phase 1 trials of preventive
HIV candidate vaccines in 2011–2012 at two clinical research centers in Nairobi. After informed consent to a mucosal sub-
study, participants were asked to undergo collection of mucosal secretions (saliva, oral fluids, semen, cervico-vaginal and
rectal), but could opt out of any collection at any visit. Specimens were collected at baseline and two additional time points.
A tolerability questionnaire was administered at the final sub-study visit. Of 105 trial participants, 27 of 34 women (79%) and
62 of 71 men (87%) enrolled in the mucosal sub-study. Nearly all sub-study participants gave saliva and oral fluids at all
visits. Semen was collected from about half the participating men (47–48%) at all visits. Cervico-vaginal secretions were
collected by Softcup from about two thirds of women (63%) at baseline, increasing to 78% at the following visits, with
similar numbers for cervical secretion collection by Merocel sponge; about half of women (52%) gave cervico-vaginal
samples at all visits. Rectal secretions were collected with Merocel sponge from about a quarter of both men and women
(24%) at all 3 visits, with 16% of men and 19% of women giving rectal samples at all visits.
Conclusions: Repeated mucosal sampling in clinical trial participants in Kenya is feasible, with a good proportion of
participants consenting to most sampling methods with the exception of rectal samples. Experienced staff members of
both sexes and trained counselors with standardized messaging may improve acceptance of rectal sampling.
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Introduction
In sub-Saharan Africa and other low and middle income
countries that bear the brunt of the pandemic, the dominant route
of transmission of HIV-1 is across the genital mucosa during
sexual intercourse. Immune responses, both humoral and cellular,
have been identified at mucosal surfaces and may be protective
[1,2]. As new vaccine candidates with the potential of inducing a
compartmentalized mucosal response have become available (e.g.,
Sendai virus vector, now in trial in East Africa; ClinicalTrials.gov
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Identifier NCT01705990), the ability to induce protective
responses in the mucosa is a key opportunity to control or even
halt HIV infection in its early stages [3].
Mucosal sampling in HIV preventive trials is becoming more
common, but much of the work is being conducted in North
America or Europe [4–8]. Sub-Saharan Africa, the region with the
highest HIV prevalence and incidence, will be a site of future
efficacy trials and would be the region to benefit the most from an
efficacious HIV vaccine. Additionally, there is a high likelihood of
population-specific differences in mucosal immune responses, due
to genetic factors and effects from endemic infections and
environmental factors. It is therefore important to build capacity
to collect, process, and analyze mucosal specimens at sub-Saharan
African clinical trial centers. A large body of mucosal work in
HIV-exposed but uninfected populations has already been done in
Nairobi [1,2,9].
The International AIDS Vaccine Initiative (IAVI) and the
Kenya AIDS Vaccine Initiative Institute of Clinical Research
(KAVI-ICR) of the University of Nairobi have been working
together to adapt existing mucosal sample collection and analysis
methods and test new ones in preparation for HIV vaccine clinical
trials. The current study was attached to three IAVI-sponsored
Phase 1 HIV vaccine trials in Nairobi as an optional sub-study to
assess acceptability of repeated mucosal sampling and the nature
of vaccine-induced mucosal HIV-1-specific immune responses.
This paper reviews the acceptability of a wide range of mucosal
sampling methods including rectal, oral, cervico-vaginal secretions
and semen, taken at three time points within the main vaccine trial
schedule.
Methods
This mucosal sub-study recruited participants who had enrolled
in one of three IAVI-sponsored HIV preventive vaccine trials
conducted either at the main KAVI clinical research center at the
Kenyatta National Hospital (KNH) complex or at KAVI’s
research unit in Kangemi, on the outskirts of Nairobi. The
mucosal and vaccine trial protocols were approved by the
Kenyatta National Hospital-University of Nairobi Ethical Review
Committee. After written informed consent and enrollment into
the main vaccine trial, participants underwent the informed
consent process and signed a separate consent form for the
mucosal study. Participants who did not initially consent to the
mucosal sub-study could enroll at any time before the final study
visit.
Study Participants
Eligibility criteria for the three vaccine trials included being
healthy, at low risk for HIV and between the ages of 18 and 50
(18–40 years for one trial, B002). All participants were advised to
use condoms. In addition, a long-lasting non-barrier method of
contraception, such as Depo-Provera, Norplant, intra-uterine
device (IUD) or tubal ligation was required of all female
participants of child-bearing potential (oral contraceptives were
not allowed). Female participants with an IUD were excluded
from cervico-vaginal sampling due to a risk of the IUD being
dislodged by the Softcup [10].
Vaccine Trials and Study Schedule
Participants were drawn from the following Phase 1 vaccine
trials: IAVI B002 (ClinicalTrials.gov Identifier NCT01264445),
B003 (NCT01215149), and B004 (NCT01496989), conducted at
sites in Eastern Africa, South Africa, and the USA, with the
mucosal sub-study conducted at the Kenyan sites only. In Kenya,
trials B002 and B003 were conducted in 2011–2012 at KAVI-
KNH and KAVI-Kangemi, respectively, and B004 was conducted
in 2012–2013 at KAVI-Kangemi. Mucosal specimens were
collected at three time points for each trial, with the timing
dependent on trial design: in B002 and B003, sampling was at
baseline, one month after the final vaccination and at the next
vaccine trial visit; in B004 sampling was at baseline, one month
after the prime and one month after the boost.
Study Procedures
Participants were free to opt out of any collection at any time or
to provide samples they had previously refused. Reasons for
refusing any sample collection were recorded at each visit. A
questionnaire was administered at the final mucosal study visit,
asking participants the main reason they agreed to provide
mucosal specimens, what mucosal specimens they would agree to
in future studies, and any general suggestions for making the
procedures more tolerable. Questions were open-ended. If
responses fit with a pre-determined list of responses, answers were
coded accordingly. If responses did not fit with one of the pre-set
answers, they were recorded verbatim. Up to two reasons for
refusal were collected at each visit for each sample type not given.
Saliva was collected by placing a Salimetrics Oral Swab
(Salimetrics LLC, State College, PA, USA) against the parotid
duct for 5 minutes. Oral fluid (transudate) was collected by
allowing fluids to pool in the mouth then passed into a Falcon tube
[11]. Participants were instructed not to eat or drink anything but
water for 2 hours prior to saliva and oral fluid collection.
In female participants, the Instead Softcup (Evofem Inc., San
Diego, CA, USA), was inserted by the clinician and kept in place
for 5 minutes (10 minutes for B004) to collect cervico-vaginal
secretions. The cervix was then accessed with a disposable
speculum and two pre-moistened Merocel sponges (Medtronic,
Minneapolis, MN, USA) were placed against the cervical mucosa
for 5 minutes each, serially. The Softcup and Merocel sponge
have been used to collect cervico-vaginal secretions in other
research studies [12,13]. Cervico-vaginal collection was not
performed during menstruation. If possible, samples were taken
approximately 2 days after bleeding ended, except baseline
samples, which were considered missed if the participant was
menstruating on the day of vaccination. Male participants
provided semen specimens, by masturbation, into a universal
container.
Rectal secretions were collected from both male and female
participants by accessing the rectal mucosa through a disposable
clinician-inserted proctoscope. Rectal secretions were collected
using two pre-moistened Merocel sponges placed against the rectal
mucosa for 5 minutes each, serially.
B002 and B003 participants were reimbursed a set amount at
the end of each visit, regardless of the actual collections performed.
In B004, the reimbursement structure was changed so that
participants were given a set amount per sample type in order to
reimburse participants for the significant additional time involved
in providing all specimen types as opposed to just one.
Humoral responses were assessed by anti-HIV specific IgG and
IgA ELISAs on frozen samples. Results will be published
separately.
Statistical Methods
Participants’ overall acceptance of a mucosal sampling method
was calculated as the proportion of participants who provided any
specimen for that sampling method during the study. 95%
confidence intervals for the observed proportions were estimated
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using exact (Clopper-Pearson) binomial method in PASS 2008
(NCSS, Kaysville, UT).
Due to limited sample size, the statistical comparisons were
primarily exploratory and were conducted for evaluation of any
observed site, trial or gender differences in acceptability of mucosal
sampling methods. Comparisons of categorical and continuous
factors were conducted using the Fisher’s exact test and Wilcoxon
rank-sum test, respectively. A two-sided p-value of less than 0.05
was considered to be statistically significant. Statistical analyses
were performed using SAS version 9.3 (SAS Institute Inc., Cary,
NC).
Results
Participant Characteristics at Enrollment
Male participants in the vaccine trials outnumbered female
participants 2:1 overall and this disproportion was also reflected in
the mucosal sub-study. 27/34 (79%) females and 62/71 (87%)
males consented and enrolled in the mucosal sub-study (p = 0.11,
Table 1). Participant ages ranged from 18 to 46 years. B002
participants were significantly younger (p,0.0001) than partici-
pants in the other two trials due to the stricter age criteria specified
in the protocol. Most female participants in all three trials were on
an injectable hormonal contraceptive (Depo-Provera), although a
few used Norplant or had a tubal ligation. Three female
participants had an IUD and were therefore excluded from
cervico-vaginal collection.
Of 16 vaccine trial participants that were not enrolled in the
mucosal study, seven participants cited discomfort or fear of the
sampling methods, two refused without giving a specific reason, for
two participants the consent form was not yet available in the local
language, and one participant each reported not wanting more
procedures, lack of time or parental advice against joining. One
participant was excluded for vertebral and pelvic bone deformities
and one participant was not enrolled because vaccinations were
discontinued following an adverse event not related to vaccination.
Participants who declined participation in the mucosal study did
not differ significantly in gender and age characteristics from those
who participated.
Acceptability of Sample Collection
Saliva and oral fluids, the least invasive samples, were collected
from all participants in the mucosal sub-study at nearly all visits,
while rectal sample collection was the least likely to be accepted
(Figure 1). Based on overall acceptance and corresponding 95%
confidence intervals, female participants agreed to both types of
cervico-vaginal sampling more readily than rectal sampling
(Table 2). Similarly, male participants were more likely to provide
semen than rectal samples.
Cervico-vaginal sampling by Softcup and Merocel sponge was
well-accepted and tolerated by the majority of women. Of 27
female participants, 18 (67%) had cervico-vaginal samples
collected with Merocel sponge at baseline and 17 (63%) also had
cervico-vaginal samples collected with Softcup (Table 3). Consent
for cervico-vaginal sampling remained consistent across the two
follow-up visits. Most missed samples were attributable to
menstruation or IUD; only three participants refused cervico-
vaginal sampling because of physical or emotional discomfort (data
not shown). Participants in B004 were given the choice of self-
inserting the Softcup or having a clinician place the device. All
participants chose to have a clinician insert the Softcup.
Overall, semen was provided by 30 out of 62 (48%) male
participants across all studies at baseline, with a similar percentage
(29/62, 47%) at the second and third visits (Table 3). There was a
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significant difference in the proportion of male participants
providing any semen specimen in B002, conducted at the KNH
clinic (32%) and in B003 and B004, conducted at the Kangemi
clinic (68%, p= 0.01). Among participants who did not provide
semen specimens, approximately half cited embarrassment/
emotional discomfort as the main reason. Another 8 (23%) were
specifically uncomfortable about masturbating at the clinic
(Table 4).
Rectal secretions were collected with Merocel sponge from 21/
89 (24%) male and female participants at each of the three visits,
however the male to female ratio differed slightly with each visit
(Table 3). Overall, there was no significant difference in the
proportion of participants providing any rectal sponge specimens
between females (41%) and males (26%) (Table 2; p = 0.21). The
proportion of participants who provided any rectal specimen was
similar for B002 and B003 (16% combined), but significantly
larger for B004 participants (56%) (data not shown; p = 0.0002). A
slight downward trend over time in B002 and B003 was reversed
in B004, with more participants agreeing to rectal sampling at the
second and third visits compared to baseline (Table 3).
When asked at the final mucosal study visit the reason for
agreeing to provide specimens, contribution to HIV research was
the primary reason given (50–64% for various specimen types),
finding out more about one’s health ranked second (20–32%),
belief that the samples were a requirement ranked third (4–12%),
belief that the study would help them access more health care
ranked fourth (4–5%), and ‘‘easiness of giving’’ was specified as
another reason for providing specimens (3–9%, with the highest
rate being for saliva). When asked for suggestions to improve the
Figure 1. Total number of participants undergoing mucosal
collection by gender. A. Total number of female participants in the
three trials combined and the number providing each type of specimen
at the three time points. B. Total combined number of male participants
and the number providing specimens at each time point.
doi:10.1371/journal.pone.0110228.g001
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Table 3. Number of participants providing specimens at each visit.
# Participants Giving Samples
Baseline (%)
# Participants Giving Samples Second
Visit (%)
# Participants Giving Samples Final Visit
(%)
Female Male Female Male Female Male
B002 Saliva 8 (89) 26 (93) 9 (100) 28 (100) 9 (100) 28 (100)
B002 Semen N/A 9 (32) N/A 8 (29) N/A 7 (25)
B002 Softcup 6 (67) N/A 7 (78) N/A 6 (67) N/A
B002 Cervical Sponge 6 (67) N/A 7 (78) N/A 6 (67) N/A
B002 Rectal Sponge 2 (22) 3 (11) 2 (22) 3 (11) 1 (11) 3 (11)
B003 Saliva 8 (100) 20 (100) 8 (100) 20 (100) 8 (100) 20 (100)
B003 Semen N/A 12 (60) N/A 12 (60) N/A 13 (65)
B003 Softcup 3* (38) N/A 6 (75) N/A 7 (88) N/A
B003 Cervical Sponge 4* (50) N/A 5 (63) N/A 6 (75) N/A
B003 Rectal Sponge 2 (25) 6 (30) 1 (13) 2 (10) 1 (13) 2 (10)
B004 Saliva 10 (100) 14 (100) 10 (100) 14 (100) 10 (100) 14 (100)
B004 Semen N/A 9 (64) N/A 9 (64) N/A 9 (64)
B004 Softcup 8 (80) N/A 8 (80) N/A 8 (80) N/A
B004 Cervical Sponge 8 (80) N/A 8 (80) N/A 8 (80) N/A
B004 Rectal Sponge 3 (30) 5 (36) 7 (70) 6 (43) 7 (70) 7 (50)
Total Saliva 26 (96) 60 (97) 27 (100) 62 (100) 27 (100) 62 (100)
Total Semen N/A 30 (48) N/A 29 (47) N/A 29 (47)
Total Softcup 17 (63) N/A 21 (78) N/A 21 (78) N/A
Total Cervical Sponge 18 (67) N/A 20 (74) N/A 20 (74) N/A
Total Rectal Sponge 7 (26) 14 (23) 10 (37) 11 (18) 9 (33) 12 (19)
*Two women missed baseline cervico-vaginal samples due to menstruation.
doi:10.1371/journal.pone.0110228.t003
Table 4. Main reason specimen not collected (reported at first refusal) – number of participants (% of refusals).
Specimens Semen Softcup Cervical Sponge Rectal Sponge
Too invasive 6 (8)
Physical discomfort or pain 2 (15) 1 (8) 19 (26)
Embarrassment/emotional discomfort 17 (49) 2 (15) 2 (15) 34 (46)
Partner/family disapproval 1 (3)
Uncomfortable masturbating in the clinic 8 (23)
Concern about inability to provide required specimen on demand 1 (3)
Procedures too time consuming 1 (3) 1 (1)
Menstruating 4 (31) 4 (31) 1 (1)
Clinician decision that collection is contraindicated 3 (23) 2 (15)
Discomfort with the clinician 1 (1)
Difficulty masturbating 4 (11)
Religious reasons 2 (6) 5 (7)
Being in a hurry 1 (3) 1 (1)
Pregnancy 1 (8) 1 (1)
Site decision 1 (8) 1 (8) 2 (3)
Being scared about the procedure 1 (8)
Not wanting rectal exam 2 (3)
Procedure being unnatural 1 (1)
Not reported 1 (8) 1 (8)
doi:10.1371/journal.pone.0110228.t004
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mucosal sampling experience, 32 out of 89 (36.0%) participants
said they had no problems or issues with the sampling methods in
this study and 28/89 (31.5%) had no comments. Suggestions to
improve semen sampling included quieter rooms, provision of
pornographic materials (not used in this study due to Kenyan anti-
pornography law) or allowing partners to assist the participant.
Rectal sampling was another area of focus, with suggestions to use
a smaller proctoscope or to find a method without the need for a
proctoscope. Suggestions are summarized in Table S1.
Discussion
This study aimed to assess the acceptability of various mucosal
sampling methods in healthy, adult, HIV-uninfected Kenyan
clinical trial participants over the course of three visits. While the
study was done within the context of HIV vaccine trials, the results
apply to any type of study requiring mucosal sampling. The
acceptability, as measured by proportion of samples collected,
varied by sample type. Saliva was easily accessed and given by all
participants. Cervico-vaginal and semen sample collection rates
were not as high as saliva but many participants consented to the
procedures and those that did remained consistent across visits.
Rectal sampling was the least acceptable, with significant variance
between study sites.
Cervico-vaginal sample collection had high acceptability and
tolerability, but many samples were missed because of menstru-
ation at baseline, or because the participants had IUDs. Although
the IUD exclusion was connected to the Softcup, the protocol was
written in such a way that IUDs excluded participants from all
cervico-vaginal collection. Otherwise, the rate of cervico-vaginal
sponge collection may have been higher. The three women who
refused cervico-vaginal sampling cited physical and emotional
discomfort as their reasons.
The Softcup is a well-accepted device for collection of menstrual
fluid by self-insertion [14] and has been used to obtain self-
collected cervico-vaginal specimens in clinical trials [15]. It was
therefore chosen for this study to collect undiluted samples with
the hypothesis that a self-inserted method would improve
acceptability. Yet when participants were given the option of
self-insertion, all chose clinician insertion of the Softcup. Perhaps
non-familiarity with the Softcup device in this population
contributed to this phenomenon; a survey by Rositch et al
reported 82% acceptability of self-sampling for pap-smear
screening among women in Nairobi [16]. Larger studies of
women from different cultures to further understand their
preferred methods for collection of genital mucosal samples are
needed. The aversion to self-inserting the Softcup in this
population would seem to abrogate its perceived benefit. It was
thought that using a dry Merocel sponge might disrupt the
mucosal epithelium, however the pre-wet sponge results in a
diluted sample. The use of dry sponges and other cervico-vaginal
collection methods should be further explored.
Semen samples were more acceptable at the Kangemi center
than at the KNH center. A possible contributor to the difference
was that private rooms were more readily available at Kangemi
than KNH at the time of the study. Additionally, all the clinic
personnel at KNH were female as opposed to Kangemi, which
had one male nurse and a male clinical officer. Some participants
declined or were unsuccessful in providing a semen sample the
same day as other samples but did so without any problems on a
return visit when fewer specimens were collected. This suggests
that multiple complex specimen collections at a single visit may be
less feasible.
Collection of rectal secretion with Merocel sponge was the most
challenging. Differences between the studies could be attributable
to a number of factors. One possible explanation is that the staff at
one site were relatively inexperienced with rectal sampling initially,
but became more adept by the time the next study was conducted.
It is conceivable that word spread amongst the participants in the
last study that the procedure was tolerable. Additionally, the staff’s
increased familiarity and comfort with rectal sampling may have
come through in the counseling process, increasing the partici-
pants’ willingness to consent.
Another contributing factor may have been the different
reimbursement schemes. B002 and B003 participants received
the same reimbursement whether they gave rectal samples or not.
B004 participants received additional reimbursement for each
sample type they agreed to. Although rectal specimen collection
was significantly greater in B004 compared to B002 and B003, no
one, including B004 participants, cited money as the reason they
gave any particular sample. More than half reported that they
gave samples for altruistic reasons. Without a comparison group at
the same site at the same time, it is difficult to draw any
conclusions about the impact of the different reimbursement
schemes.
It is discouraging that despite an in-depth information session(s)
and consent process, 4–12% of the participants, depending on
sample type, gave the sample because they thought it was
required. In the clinical trials that this mucosal sub-study was
nested, blood draws were a requirement; it is therefore possible
that participants may have assumed that the same requirement
applied to the mucosal samples, especially since specimen
sampling for the two studies coincided. It is also likely that
participants understood they had a choice about which samples to
provide when they first entered the study, but may have thought
that once they agreed to something it was required for the
remaining visits. We recommend that consent forms include a
section where the participant can indicate which sampling
methods they consent to. Since the consent form is signed at the
beginning of the study, we also recommend verbal confirmation of
which samples the participant is agreeing to at each visit. This
should be documented in writing in clinic notes or other source
documents. KAVI is currently conducting a clinical trial with these
added precautions. We plan to compare participants’ reasons for
agreeing to provide specimens across these studies and see if this
additional step has improved understanding of the study
requirements.
Study Limitations
The demographic data collected in the three vaccine trials were
limited to age, gender, and race/ethnicity. As a result, other
information such as marital status, education, parity for women
and socio-economic differences could not be examined. The study
participants were selected for their low risk of HIV infection, and
their knowledge, attitudes and flexibility may differ from people
who are at higher risk, particularly sex workers.
The mucosal sampling time points in each trial were dependent
on the vaccination schedules, which varied between protocols. The
length of the gap between the second and third visits did not
appear to have affected compliance.
The informed consent process was similar between the two sites,
but scripts were not used to explain the procedures. Individual
differences between counselors could have affected the likelihood
of enrollment. Without a strictly standardized method of
explaining the procedures, it is possible the consent process had
an impact on the initial acceptability of the various sample types.
This is an area for further development and research.
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Conclusions
Repeated mucosal sampling including saliva, oral fluids, semen,
cervico-vaginal and rectal specimens in healthy, adult, HIV-
uninfected clinical trial participants in Kenya is feasible. Partic-
ipants consented to most specimen collection methods with the
exception of rectal sampling. Given the high HIV incidence
demonstrated in MSM populations in Africa [17], rectal mucosal
sampling should not be dismissed because of its challenges.
Experienced staff members that include both men and women,
well-trained counselors and standardized language during the
informed consent process may improve acceptability of rectal and
other sampling.
Supporting Information
Table S1 Participant suggestions for improving muco-
sal sampling experience, n=89.
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